Literature DB >> 27085542

Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients.

Martin A Bishop1, Michael B Streiff2.   

Abstract

Anticoagulation (AC) clinics use the percentage of time in the therapeutic INR range (%TTR) to characterize the quality of management for patients treated with warfarin. In order to guide policy and procedure changes, the purpose of this quality improvement (QI) study was to characterize the AC patient population at The Johns Hopkins Hospital (JHH). We set out to investigate the impact of AC clinic provider continuity on the quality of anticoagulation management. This QI study is a retrospective chart review of 525 warfarin patients managed by pharmacists in the Hematology AC Management Clinic at JHH from June 28, 2013 to November 1, 2014. We recorded patient demographic and clinical characteristics and the quality of AC management using %TTR, and compared these parameters between patients with (Group A) and without a primary AC (Group B). Group A patients had a significantly higher %TTR than Group B patients (53.2 vs. 46.5 %, p = 0.008). In conclusion, we found that patients with a primary AC clinic provider had a higher %TTR than patients with multiple providers. If confirmed prospectively, this approach to warfarin management could represent one technique for AC clinics to optimize patient management and clinical outcomes.

Entities:  

Keywords:  Anticoagulants; International normalized ratio; Quality improvement; Venous thromboembolism; Warfarin

Mesh:

Substances:

Year:  2016        PMID: 27085542     DOI: 10.1007/s11239-016-1359-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  24 in total

Review 1.  The association between continuity of care and outcomes: a systematic and critical review.

Authors:  Carl van Walraven; Natalie Oake; Alison Jennings; Alan J Forster
Journal:  J Eval Clin Pract       Date:  2010-10       Impact factor: 2.431

2.  Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs.

Authors:  J B Segal; R L McNamara; M R Miller; N Kim; S N Goodman; N R Powe; K A Robinson; E B Bass
Journal:  J Gen Intern Med       Date:  2000-01       Impact factor: 5.128

3.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

4.  Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy.

Authors:  Daniel M Witt; Melanie A Sadler; Roberta L Shanahan; Georgann Mazzoli; Donald J Tillman
Journal:  Chest       Date:  2005-05       Impact factor: 9.410

5.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

6.  Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.

Authors:  Marcus Lind; Martin Fahlén; Mikhail Kosiborod; Björn Eliasson; Anders Odén
Journal:  Thromb Res       Date:  2011-08-17       Impact factor: 3.944

Review 7.  Systematic overview of warfarin and its drug and food interactions.

Authors:  Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells
Journal:  Arch Intern Med       Date:  2005-05-23

Review 8.  Does heart failure exacerbation increase response to warfarin? A critical review of the literature.

Authors:  Timothy H Self; Anne B Reaves; Carrie S Oliphant; Chris Sands
Journal:  Curr Med Res Opin       Date:  2006-11       Impact factor: 2.580

9.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs.

Authors:  E Chiquette; M G Amato; H I Bussey
Journal:  Arch Intern Med       Date:  1998 Aug 10-24

10.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

View more
  2 in total

1.  Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience.

Authors:  Halil Atas; Ahmet Anıl Sahin; Dilek Barutçu Atas; Murat Sunbul; Alper Kepez; Mehmet Agirbasli
Journal:  Clin Appl Thromb Hemost       Date:  2017-03-01       Impact factor: 2.389

2.  Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica.

Authors:  Jodi-Ann Mckenzie; Cameil Wilson-Clarke; Jennifer Prout; Jacqueline Campbell; Rhea-Danielle Douglas; Maxine Gossell-Williams
Journal:  Pharm Pract (Granada)       Date:  2018-11-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.